What is Dogwood Therapeutics's D&A?

Dogwood Therapeutics (DWTX) reported D&A of $17.26K in Q2 2025.

How has Dogwood Therapeutics's D&A changed year-over-year?

Dogwood Therapeutics's D&A increased by 466.8% year-over-year, from $3.04K to $17.26K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Dogwood Therapeutics DWTX D&A

D&A at other companies

Eli LillyLLY

$509M+9.9%

PfizerPFE

$1.61B-0.3%

Vertex PharmaceuticalsVRTX

$55.9M+15.5%

Collegium Pharmaceutical, Inc.COLL

$463K-57.6%

BioventusBVS

$11.21M-5.6%

Avanos MedicalAVNS

$10.2M+6.3%

Other financials

Income statement

See full

Operating income-$5.1M-14.6%

Net income-$5.0M+54.4%

EPS (diluted)-$0.15+98.2%

Balance sheet

See full

Cash & equivalents$13.2M-24.6%

Total debt$144.9K-24.2%

Total equity$80.6M+1,038%

Total assets$95.2M-1.8%

Cash flow

See full

Operating cash flow-$4.6M+2.0%

Valuation

See full

Market cap$54.14M-57.6%

Enterprise value$41.06M-64.7%

Returns & leverage

See full

Return on equity-64.6%-29.8pp

Debt / equity0×0.0×

Current ratio5.9×-1.6×

Where this comes from

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Dogwood Therapeutics’s 10-Q, filed August 13, 2025, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dogwood Therapeutics's D&A?: Dogwood Therapeutics (DWTX) reported D&A of $17.26K in Q2 2025.
How has Dogwood Therapeutics's D&A changed year-over-year?: Dogwood Therapeutics's D&A increased by 466.8% year-over-year, from $3.04K to $17.26K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.